Brief: Clinuvel Pharmaceuticals Preparing Upgrade Of ADR Program To Level II, Nasdaq Uplist
22/08/2025 03:08
Aug 22 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX: PREPARING UPGRADE OF ADR PROGRAM TO LEVEL II, NASDAQ UPLIST PRIMARY LISTING ON ASX WILL REMAIN UNCHANGED Further company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist